Genome sequencing analysis has shown that CCAAT/enhancer-binding protein-beta (C/EBPβ) enhancer, a transcription factor overexpressed in HCC patients, is repeatedly hypomethylated throughout the genome, and such hypomethylation has been shown to correlate with C/EBPβ overexpression and prognosis in HCC patients [28]. This evidence concerns the gene CEBPB and hepatocellular carcinoma.